| Title | Aripiprazole in the treatment of Huntington's disease: a case series. | | Author(s) | Ciammola A, Sassone J, Colciago C, Mencacci NE, Poletti B, Ciarmiello A, Squitieri F, Silani V | | Institution | Department of Neurology and Laboratory of Neuroscience, "Dino Ferrari" Centre, University of Milan Medical School - IRCCS Istituto Auxologico Italiano, Milano, Italy; | | Source | Neuropsychiatr Dis Treat 2009.:1-4. | | Abstract | OBJECTIVES: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington's disease (HD).
METHODS AND RESULTS: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.
CONCLUSIONS: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19557093 |
|
